AI

WellSky® to Acquire TapCloud to Bolster Patient Engagement Technology That Improves the Patient Experience and Lowers Costs

WellSky | February 24, 2022

WellSky, a global health and community care technology company, announced today that it intends to acquire TapCloud, a virtual patient engagement technology company that helps patients, caregivers, and clinicians communicate crucial information in real-time to achieve better health outcomes.

Frequent communication between patients, clinicians, and payers is critical to providing quality care and delivering on value-based care. TapCloud’s interoperable, AI-driven platform provides real-time, patient-generated insights, enabling providers to deploy care interventions aimed at reducing preventable hospital readmissions and emergency care.

“WellSky is connecting every part of health and community care, and TapCloud represents a significant addition to our suite of solutions. By adding these robust capabilities, WellSky will further extend our position as the leading technology and analytics partner across the continuum. Together, WellSky and TapCloud will enable providers to make evidence-based decisions, powered by actionable analytics. With this new level of patient visibility, our clients can achieve better outcomes, lower costs, and ultimately, succeed in value-based care.”

Bill Miller, CEO of WellSky

Using TapCloud’s EHR-agnostic patented technology, patients can share their symptoms and other pertinent data with providers using virtual visit technology, secure messaging, and remote symptom screening protocols. The combination of TapCloud’s user-friendly technology and WellSky’s deep experience in predictive analytics opens new possibilities for providers and payers as they seek to increase collaboration and better coordinate care.

“TapCloud has worked tirelessly to close the communication gap between patients and providers through the use of data and technology. With WellSky, we gain access to a larger network and increased investment, which will broaden our reach and allow even more patients and families to be active participants in their care journeys,” said Phil Traylor, CEO of TapCloud. “Together, we are well-positioned to expand the ways we can help our clients be successful, no matter which EHR platform they use. I’m excited to see how we will innovate together.”

WellSky will integrate TapCloud’s platform into its healthcare technology solutions that more than 5 million caregivers use each day. Over time, WellSky will expand its extensive clinical dataset to include TapCloud’s patient-generated data, enabling the development of new models that allow providers, payers, and other risk-bearing entities to better predict patient risk factors and deploy interventions.

The transaction is subject to customary closing conditions and is expected to close shortly.

About WellSky®

WellSky is a technology company leading the movement for intelligent, coordinated care. Our next-generation software, analytics, and services power better outcomes and lower costs for stakeholders across the health and community care continuum. In today’s value-based care environment, WellSky helps providers, payers, health systems, and community organizations solve tough challenges, improve collaboration for growth, harness the power of data analytics, and achieve better outcomes by further connecting clinical and social care. WellSky serves more than 20,000 client sites — including the largest hospital systems, blood banks, cell therapy labs, blood centers, home health and hospice franchises, post-acute providers, government agencies, and human services organizations. Informed by more than 40 years of providing software and expertise, WellSky anticipates clients’ needs and innovates relentlessly to ultimately help more people thrive. 

About TapCloud

TapCloud is a virtual patient engagement platform that helps patients, caregivers, and clinicians communicate crucial information in real time to achieve better health outcomes. Our core premise is that how a patient feels – pain levels, specific symptoms, overall trajectory, emotional well-being – is the earliest and best predictor of who is most likely to need or seek care within the next few days. Our approach to capturing and distilling that information is unique, with tools such as our patented AI-driven world cloud that captures the equivalent of a 30-40 question survey in less than 10 seconds. As a result, patients check in with TapCloud an average of 4 times per week. 

Spotlight

How many times a day do you think patients and visitors stop hospital employees to ask for directions, hopelessly confused in the maze of hallways? Poor hospital navigation has a host of (very expensive) effects, but it can be remedied…

Spotlight

How many times a day do you think patients and visitors stop hospital employees to ask for directions, hopelessly confused in the maze of hallways? Poor hospital navigation has a host of (very expensive) effects, but it can be remedied…

Related News

HEALTH TECHNOLOGY

Eleos Health and The Echo Group Announce Strategic Partnership to Advance the use of Augmented Intelligence in Behavioral Health

Eleos Health and Echo Group | September 16, 2022

Eleos Health, the leader in CareOps Automation for behavioral health, and The Echo Group, the only provider of visual electronic health record technology, announced that Eleos Health's augmented intelligence will be directly embedded into the EchoVantage web-based clinical, billing, and administrative EHR application to serve the needs of behavioral healthcare clinicians. Eleos Health and EchoVantage will act in synergy to reduce administrative burdens on clinicians. Medical professionals face an increasing number of administrative tasks, spending an average of 20% of their total working hours on administration. In general, notes for each session take about 15 minutes to complete, with the average full-time clinician doing so for 40 sessions per week. Eleos will turn behavioral health conversations into documentation and session intelligence, plugging directly into EchoVantage's visual health record (VHR). The VHR provides clinicians with a client's case across a timeline, with visual indicators providing an understandable and actionable graphical format. Clinicians using Eleos reduce time spent on documentation by over 30%. This increase in efficient and accurate documentation also equips supervisors with unprecedented visibility into staff activity, caseloads and performance to make it easier for providers to meet organizational standards for documentation, while empowering providers to improve training with structured, objective feedback on their sessions. "Eleos Health is excited to add The Echo Group to our growing base of strategic partners who are dedicated to advancing the standard of care in behavioral health. By enhancing the EchoVantage EHR with our augmented intelligence capabilities, we will give clinicians the ability to spend less time on administrative tasks and more time impacting the lives of those managing behavioral health conditions," Alon Joffe, CEO and Co-Founder, Eleos Health EchoVantage ensures that all aspects of the clinical chart are fully integrated and organized, along with the timeline, in relation to each other. This lends true clinical understanding to precipitating events and treatment activities. "The expansion of our national offering to include Eleos Health as an embedded platform for all of our customers is a huge benefit for clinicians and their patients," said Allan Normandin, Chief Executive Officer, The Echo Group. "The Echo Group is focused on finding ways to empower our customers to be more clinically effective and financially strong. Working with Eleos Health is another step in achieving that goal by reducing the barrier of administrative tasks in the continuum of care." This partnership puts overburdened clinicians back into the office working with clients instead of spending their time typing notes into their EHR. Beyond simplifying documentation, , this partnership will enable clinicians to quickly understand the themes in their meetings, such as suicidal thoughts or cognitive-behavioral therapy techniques, and pursue the best evidence-based practices. Eleos Health's proprietary voice-based Natural Language Understanding (NLU) technology accurately identifies evidence-based techniques, as well as interprets the meaning of behavioral health conversations, giving clinicians objective feedback they can use with patients to identify recurring themes, issues and needs. Eleos Health will be available to all of The Echo Group's clients as an add-on, with GRAND Mental Health, in Northeastern and North Central Oklahoma, being the first center to leverage the power of both systems to help give its care providers more time for patients. The Echo Group's partners are located throughout the U.S. and range in size, from small community behavioral health agencies to comprehensive enterprise-wide organizations. "The ability to reduce administrative burdens for clinicians while also increasing visibility around the quality of care is invaluable in giving our staff the freedom and tools they need to focus on our mission of improving quality of life for consumers," said Josh Cantwell, COO, GRAND Mental Health. "The Eleos Health and Echo Group partnership will meaningfully ability to support clinicians and serve our communities." About Eleos Health Founded in 2020, Eleos Health turns behavioral health conversations into documentation and intelligence that drives better care. Using proprietary, voice-based Natural Language Understanding (NLU) technology built by clinical experts to accurately interpret, analyze and document behavioral health conversations, Eleos reduces the operational burden on providers while unlocking objective insights into evidence-based care and the therapeutic alliance. Leadership teams can scale supervision and training while gaining unprecedented visibility into staff activity, caseloads and performance as well as population health. Eleos is the only technology of its kind that embeds seamlessly into electronic health records (EHRs), telehealth tools and existing provider workflows. With Eleos CareOps Automation, behavioral health providers are setting a new standard for care. About The Echo Group The Echo Group, privately held since 1980, revolutionized electronic health records in the behavioral health industry with EchoVantage, the only EHR featuring a visual continuum of care timeline. EchoVantage is a core, integrated EHR platform with a complete suite of tools designed to conform to your workflow, meet compliance requirements, and increase productivity, enabling you to spend more time putting your clients. The Echo Group is located in Conway, New Hampshire, with an additional office in California. Echo has more than 80 employees dedicated to making the best behavioral health technology in the industry.

Read More

HEALTH TECHNOLOGY

Sense and TECOmedical Sign Distribution Agreement for Germany, Austria, Switzerland

Sense Biodetection | September 02, 2022

Global molecular diagnostics innovator, Sense Biodetection announced it has entered into a strategic agreement with TECOmedical for the non-exclusive distribution of Sense’s Veros COVID-19, the first test on the rapid, instrument-free, point-of-care Veros molecular testing platform. The self-contained, single-use Veros COVID-19 product produces PCR-quality results in about 15 minutes, unconstrained by a reader or need for external power. TECOmedical, a Eurobio Scientific Company, is a leading specialty medical distributor with proven success developing new markets with innovative technology. Effective immediately in Germany and Austria, and pending regulatory approval in Switzerland, the agreement is the latest in Sense’s planned EU distribution partnerships as it commercializes its Veros platform. “We are delighted to partner with TECOmedical to bring Veros COVID-19 to the market, building on the impressive reputation that TECOmedical has established with their customers,” stated Ryan Roberts, Chief Commercial Officer of Sense. “We’re optimistic that by adding the instrument-free Veros COVID-19 to their diagnostic portfolio, TECOmedical’s customers will be able to take advantage of a laboratory-quality molecular test that can enable improved access and faster diagnosis, helping them to provide exceptional care for their patients right at the point of use.” “We are always looking for innovative technologies that address an unmet need. Being able to offer an instrument free, PCR-quality result in minutes right at the Point of Care reflects our commitment to customers to bring solutions that help them overcome limitations of existing technologies and improve care. We are excited to launch Veros COVID-19 now and are eagerly anticipating an expanded Veros test menu in the future.” Marieluise Wippermann, CEO of TECOmedical Veros is the first and only instrument-free, single-use, rapid, point-of-care molecular diagnostic testing platform that produces lab-quality results in about 15 minutes. Using a proprietary, rapid molecular amplification technology, Veros aims to help to improve access to rapid, highly accurate, point of care testing for many more people, and help reduce the spread of COVID-19 with faster, more precise diagnoses. Veros COVID-19’s clinical performance was established in one of the most comprehensive clinical trials in COVID-19 diagnostic testing conducted to date. The multicentre study prospectively enrolled nearly 300 evaluable subjects during both the Delta and Omicron variant surges of the pandemic. All study sites represented near-patient testing / point-of-care environments, with all test operators reporting no prior formal laboratory training or experience. 100% of operators agreed the Veros COVID-19 was easy-to-use, read and understand the results, with minimal hands-on time required from start to finish. As the virus continues to evolve, Veros COVID-19 has maintained 100% conservation in all Variants of Interest and Concern identified to date by WHO and the US CDC, including all Omicron sub-variants. About Sense Biodetection Sense Biodetection is a global molecular diagnostics company focused on empowering patients and transforming healthcare access and affordability by bringing lab-quality results through easy-to-use, rapid, disposable molecular tests without the constraints of an instrument. The company's Veros product platform will enable widespread testing to enhance patient access, improve patient health and lower systemic healthcare costs. Backed by respected investors, such as Koch Disruptive Technologies, Cambridge Innovation Capital, Earlybird Health and Mercia Asset Management, Sense has launched its first product, Veros COVID-19, and is growing rapidly while building a portfolio of tests for other diseases. About TECOmedical The Swiss-based TECOmedical Group, a Eurobio Scientific company, with subsidiaries in Germany and Austria is a leading provider of in-vitro specialty test systems in medical diagnostic, based on Immunosorbent, Immunofluorescence and Molecular methodologies.

Read More

HEALTH TECHNOLOGY

Veranex Expands European MedTech Capabilities With Acquisition of Medidee

Veranex and Medidee Services | September 21, 2022

Veranex, the only truly comprehensive, global, tech-enabled service provider dedicated to the medical technology industry, announced that it has acquired Medidee, a top MedTech consultancy company headquartered in Lausanne, Switzerland. As a trusted European regulatory and quality service consultancy joining Veranex, Medidee expands and strengthens regulatory affairs, clinical development, and quality assurance services and capabilities for MedTech companies across Europe and the world. This improved ability to navigate the European Union’s Medical Device and In Vitro Diagnostic Device Regulations challenges supports truly full-service MedTech product development and commercialization. “Our acquisition of Medidee significantly expands our European footprint while also materially expanding the scale and scope of the clinical studies we can manage. The combined organization offers offices and expertise across Europe, the U.S., and Asia, augmenting our ability to help MedTech innovators achieve FDA and CE Mark approvals and uninterrupted market access for new as well as proven medical technologies that advance patient care.” Veranex CEO David Dockhorn With Medidee’s 11 locations across Europe, India, and Asia-Pacific, and Veranex’s 13 locations across the U.S., Europe, and China, the company now has unprecedented reach to serve clients with a full spectrum of integrated concept-to-commercialization services — design, engineering, regulatory, quality, preclinical research, clinical development, clinical operations, commercial strategy, and market access services — all under one umbrella. Medidee is one of the Top 3 medical device consultancy service providers in Europe uniquely positioned as a leader in future key areas such as digital health, machine learning, and cybersecurity. The company also brings expertise in clinical research exclusively focused on medical devices and in vitro diagnostics. “Medidee has a proven track record serving regulatory, clinical, and quality needs for companies of all sizes, with consulting expertise and clinical trial support in increasingly diverse therapeutic areas and technology categories across multiple geographies,” shared Medidee co-founders Kim Rochat, Philippe Etter, and Michael Maier. “With these services, coupled with the global infrastructure of Veranex, we expand expertise and resources for the benefit of our clients as well as for all EU innovative manufacturers wishing to access rapidly and efficiently the U.S. market and beyond. We look forward to providing these additional strengths and capabilities,” added the co-founders who take on new roles in the combined organization. About Veranex Veranex is the only truly comprehensive, global, tech-enabled service provider dedicated to the medical technology industry. Offering expert guidance from concept to commercialization and across the development continuum, Veranex enables accelerated speed to market, controlled development costs, development risk mitigation, and accelerated market viability assessment. At every stage, Veranex customers realize efficiencies in cost and time, while its comprehensive solutions unify and streamline the entire development process. Veranex is backed by Summit Partners, Accelmed, and Lauxera Capital Partners. About Medidee Services With sites in Switzerland, Germany, Denmark, Belgium, Spain, USA, and APAC, Medidee is a global services supplier serving companies ranging from academic startups to majors. Medidee was established by three partners, all experts in the field of medical devices. With 50 experts in all fields necessary to ensure compliance with the most stringent requirements, Medidee provides the necessary competencies to ensure and demonstrate compliance with all key medical device regulations. Medidee expends regularly to provide the best resources and competencies and supports more than 350 manufactures all over the world.

Read More